Fig. 2
Effect of CD47 blockade on the patient-derived PDAC xenograft models. a Schematic of patient-derived PDAC xenograft establishment and tumor immunotherapy design. b Staining with an anti-CD47 antibody in two human PDAC tissue samples P962 and P989 at × 100 magnification and × 400 magnification (upper panels). H&E and anti-CD47 antibody staining of tumor tissues from P962 and P989 patient-derived xenograft models (P2 generation) at × 100 magnification and × 400 magnification (lower panels). Scale bar = 50 μm (red line at the bottom left). c–h P962 and P989 xenografts from nude and NCG mice were treated intraperitoneally with IgG control or anti-CD47 mAb at 200 μg/day for 2 weeks. Each group contained five animals. Tumor volume and weight were then measured (d, e, g, and h). (i–k) Panc02 cells were transplanted to C57BL/6 mice. When the tumor reached 100 mm3, tumor-bearing mice were treated with anti-CD47 antibodies for 14 days. Tumor volume and weight were then measured (j, k)